Evidence map›Paper›PMID 29755970›Full record

ArticleFrontiers in chemistry2018

How to Achieve Better Results Using PASS-Based Virtual Screening: Case Study for Kinase Inhibitors.

Pavel V Pogodin, Alexey A Lagunin, Anastasia V Rudik, Dmitry A Filimonov, Dmitry S Druzhilovskiy, Mark C Nicklaus, Vladimir V Poroikov

Abstract read
In one paragraph

Article in Frontiers in chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Mutant-Selective Binding ofInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Deep Learning Pipeline for Accelerating Virtual Screening in Drug Discovery.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  6. Article
  7. Modification of B-Nor Steroids Mediated by Filamentous FungusInternational journal of molecular sciences · 2024
    Article
  8. Article
  9. Acta pharmaceutica Sinica. B · 2024
    Review
  10. Article
  11. Screening for potential novel probioticFrontiers in microbiology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. QSAR without borders.Chemical Society reviews · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pavel V PogodinDepartment of Bioinformatics, Institute of Biomedical Chemistry, Moscow, Russia.
Alexey A LaguninDepartment of Bioinformatics, Institute of Biomedical Chemistry, Moscow, Russia.
Anastasia V RudikDepartment of Bioinformatics, Institute of Biomedical Chemistry, Moscow, Russia.
Dmitry A FilimonovDepartment of Bioinformatics, Institute of Biomedical Chemistry, Moscow, Russia.
Dmitry S DruzhilovskiyDepartment of Bioinformatics, Institute of Biomedical Chemistry, Moscow, Russia.
Mark C NicklausComputer-Aided Drug Design Group, Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, NIH, NCI-Frederick, Frederick, MD, United States.
Vladimir V PoroikovDepartment of Bioinformatics, Institute of Biomedical Chemistry, Moscow, Russia.

Funding

Tools for Prediction of Drug Metabolism and MetabolitesZIABC011336 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NICKLAUS, MARC · 2010 to 2020
$1.2M
6 · The paper itself

Abstract

Discovery of new pharmaceutical substances is currently boosted by the possibility of utilization of the Synthetically Accessible Virtual Inventory (SAVI) library, which includes about 283 million molecules, each annotated with a proposed synthetic one-step route from commercially available starting materials. The SAVI database is well-suited for ligand-based methods of virtual screening to select molecules for experimental testing. In this study, we compare the performance of three approaches for the analysis of structure-activity relationships that differ in their criteria for selecting of "active" and "inactive" compounds included in the training sets. PASS (Prediction of Activity Spectra for Substances), which is based on a modified Naïve Bayes algorithm, was applied since it had been shown to be robust and to provide good predictions of many biological activities based on just the structural formula of a compound even if the information in the training set is incomplete. We used different subsets of kinase inhibitors for this case study because many data are currently available on this important class of drug-like molecules. Based on the subsets of kinase inhibitors extracted from the ChEMBL 20 database we performed the PASS training, and then applied the model to ChEMBL 23 compounds not yet present in ChEMBL 20 to identify novel kinase inhibitors. As one may expect, the best prediction accuracy was obtained if only the experimentally confirmed active and inactive compounds for distinct kinases in the training procedure were used. However, for some kinases, reasonable results were obtained even if we used merged training sets, in which we designated as inactives the compounds not tested against the particular kinase. Thus, depending on the availability of data for a particular biological activity, one may choose the first or the second approach for creating ligand-based computational tools to achieve the best possible results in virtual screening.

Indexed as

bioactivity dataChEMBLclassificationkinase inhibitorsPASSSARSAVIvirtual screening

Identifiers

PMID29755970
PMCPMC5935003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.